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SUMMARY
The establishment of hybridomas after fusion of X63-Ag8.653 mouse myeloma cells and splenocytes from BALB/c mice hyperimmunized against human astrocytomas is presented. The animals were primed with 5 x 106 chemically modified uncultured or cultured glioma cells. Six weeks after the last immunization step an intrasplenal booster injection was administrated and 3 days later the spleen cells were prepared for fusion experiments. According to the specificity analysis of the generated antibodies 7 hybridoma products react with gliomas, neuroblastomas and melanomas as well as with embryonic and fetal cells but do not recognize non-neurogenic tumors. The selected monoclonal antibodies (McAbs) of IgG~ and IgG2a isotypes are not extensively characterized but these antibodies have been demonstrated to be reactive with a panel of glioma cell lines with varying patterns of antigen distribution. Using the McAbs described above and a series of cryosections of glioma biopsies and paraff'm sections of the same material as well as glioma cultures established from these, variable antigenic profiles among glioma cell populations could be demonstrated. From these results it is evident that there is not only a distinct degree of antigenic heterogeneity among and within brain tumors, but also that the pattern of antigenic expression can change continuously. Some of the glioma associated antigens recognized by the selected INTRODUCTION The development of adequate immunologic methods is a fundamental condition for the investigation of membrane alterations and the resulting antigenicity of tumor cells. By the establishment of the hybridoma technique (KOhler and Milstein 1975) and the use of monoclonal antibodies (McAbs) in the analysis of the antigenic determinants of the tumor cell membrane, not only the existence of tumor associated antigens in spontaneous and experimental brain tumors has been demonstrated (Schnegg et al. 1981; Sikora and Phillips 1981; Coakham et al. 1982; Wikstrand and Bigner 1982; Stavrou et al. 1983; de Muralt et al. 1985) , but also efforts in developing valuable diagnostic methods received considerable stimulation (review by Bullard and Bigner 1985) . Numerous attempts have been made to produce McAbs which recognize glioma cells exclusively. So far, there is a number of monoclonal reagents binding antigens expressed on tumor cells but also on normal glia cells (Krajewski et al. 1986) .
In order to generate molecules useful to assist in the more accurate and objective typing of intracranial malignancies we established immunoglobulin secreting hybridomas using cultured and uncultured human astrocytoma cells as antigen. In the following we describe the recognition pattern of selected McAbs with their high degree of specificity utilizing cell cultures of different origin as well as tissue samples obtained from neurogenic and non-neurogenic tumors and normal organs.
MATERIALS AND METHODS

Human lumors
Fresh tumor samples from biopsy material were immediately frozen and preserved in liquid nitrogen containers or bio-freezers until use for histochemistry or immunization. Additional tumor specimens were fixed in Bouin's solution, Karnovsky's fixative and methanol/acetone mixture and embedded in paraffin (45 °C). Sections of frozen and paraffin material were used for conventional histology as well as for immunohistochemistry. For control experiments tissue fragments of different regions of normal brain and other organs were obtained 90 min post-mortem and processed analogous.
Human tumor cell cultures
For establishment of primary cultures, fragments of biopsy material obtained under sterile conditions were placed in Falcon flasks and covered with medium M 199 (with Hank's salts, Seromed ®, Berlin, F.R.G. or RPMI 1640), supplemented with 20~'o inactivated FBS (fetal bovine serum, Flow laboratories, Meckenheim, F.R.G.), 10 ml 8.8 ~ NaHCO3, 100 000 IU penicillin G, 0.1 g streptomycin, 0.1 g neomycin, and 3.4 ml 20 mM glutamin per litre medium. Cultures were incubated at 37 °C in air with 6~/o CO 2 and high humidity. For in vitro passaging of the cells, primary cultures were splitted 1 : 2 using saline trypsin-versene (STV) solution. Long term cultures were fed with M 199 or RPMI 1640 (Seromed ®, Berlin, F.R.G.), supplemented with 10~ inactivated FBS, 10 ml 8.8~o NaHCO3, 100000 IU penicillin G, 0.1 g streptomycin, and 3.4 ml (M 199) or 10 ml (RPMI 1640) 20 mM glutamin per litre medium and karyotyped from time to time.
Human embryonic cell cultures
Fragments from brain anlage as well as from thoracic and abdominal segments of two embryos (9th and 1 lth weeks of development) were layered in plastic flasks. In addition, the rest of the embryonic material was prepared as a fine cell suspension and placed in tissue culture flasks. All primary cultures were fed with HC medium (450 ml DMEM, 75 ml FBS, 50 ml NCTC-135 medium, Flow Lab., Meckenheim, F.R.G., 5 ml sodium pyruvate, 0.1 g neomycin) initially supplemented with 20 ~ inactivated FB S and the subcultures were maintained in the same medium containing 10~ FBS. Subsequently, the cultures were serially transferred using STV solution twice a week. All cultures were incubated at 37 °C humidified atmosphere of 6~ CO 2 in air.
Animals
BALB/c and BALB/c-nu/nu mice used for immunization and production of ascitic fluid were taken from our barrier maintained colony.
Mouse myeloma line
The myeloma cell line X63-Ag8.653 (Kearney et al. 1979 ) was used for fusion experiments. The myeloma cells were grown in HC medium supplemented with 10% FBS. Two days before fusion, the ceils were fed with HC medium containing 20% FBS.
Establishment of murine hybridoma clones (MUC)
BALB/c mice were immunized i.p. 3 times (lst, 8th, 15th day) with 5 x 10 6 TNBS (2,4,6-trinitrobenzenesulfonic acid) modified whole human tumor cells cultivated in vitro (85HG-3 and 85HG-63 astrocytoma cells) and with cells prepared from biopsy material of a malignant glioma (N 22/85: astrocytoma grade III). TNBS modification was carried out as described by Stavrou et al. (1980 Stavrou et al. ( , 1981 . Briefly, mechanically harvested cells (5 x 10 6) in 0.1 ml medium were incubated with 0.1 ml of 0.1 M TNB S dissolved in 0.05 M PBS (pH 7.4) for 10 min at 37 °C. Aseptically removed tumor fragments were washed with sterile PBS, immediately minced and passed through a sterile wire-gauze. The cell suspension was frozen and stored at -80 °C. Six weeks after the last immunization an intrasplenal booster injection of 5 x 105 native tumor cells, harvested from culture vessels using STV solution or thawed from frozen tumor samples, was performed. Three days later spleen ceils were fused with X63-Ag8.653 myeloma cells. Hybrids were selected as described previously (Stavrou et al. 1983 . Supernatants from hybridoma cultures were tested for antibody reactivity with glioma tissue and glioma cell cultures.
Antibody binding assays
Screening for immunoglobulin secretion by hybridomas and for identifying hybridoma clones of interest was performed using the following techniques: (a) micro-ELISA (Posner et al. 1982) ; (b) indirect immunoperoxidase stain, carried out on cells grown in Terasaki plates and on tissue sections prepared from frozen as well as from fixed (methanol/acetone, Bouin, Karnovsky) and paraffin-embedded (45 °C) material; (c) indirect immunofluorescence test as reported by Stavrou et al. (1978) ; and (d) 125I radioimmunoassay (125I-RIA) using 10 x 105 target cells incubated on U-bottomed microtest plates with culture fluid. Details of the performance protocols have been published (Stavrou et al. 1983; de Muralt et al. 1985) .
Flow cytometry analysis
Fluorescent activated cell sorter procedures were performed in buffer consisting of phosphate-buffered saline, 2.5~o fetal bovine serum, and 0.02~o NaN 3. Stained cells were analysed after fixation with 1 ~o paraformaldehyde (Lanier and Warner 1981) by flow cytometry using an EPICS 752 (Coulter Electronics). The EPICS was operated at 488nm excitation wavelength with the photomultipler tube at 650-800V. Fluorescence intensity was expressed on a log scale of 256 channels. Living cells were gated on forward angel lightscatter and 90 degree log integrated lightscatter. Indirect immunofluorescence was used for the hybridoma superuatants directed against glioma cell surface determinants. The supematants were incubated for 60 min with 106 cells on ice, followed by 2 washes with PBS, and incubated on ice with rabbit anti-mouse FITC (Dakopatts F 261).
As control, the isotype-matched irrelevant mouse myeloma protein UPC 10 (Sigma No. M-9144) diluted 1 : 100 was used.
Concentration and partial characterization of McAbs
The enrichment of McAbs from hybridoma supernatants was performed by using saturated ammonium sulfate solution (Jonak 1980) . The identification of hybridoma products was carried out by using the two-dimensional double-immunodiffusion, immunoelectrophoresis and SDS-PAGE tests. The isotype of monoclonal immunoglobulin was determined by using micro-Ouchterlony immunodiffusion and microtitration ELISA subtyping system (Mouse-typer TM sub-isotyping kit, Bio-Rad Laboratories, Richmond, LA, U.S.A.) and appropriate polyclonal antisera (Miles Laboratories, Naperville, IL, U.S.A.).
In order to estimate the binding specificity of selected hybridoma products a series of absorption experiments were performed. Hybridoma supernatants were absorbed with cultured human cells and human brain powder and the remaining activity was then tested by antibody-binding tests using cultured glioma cells as targets. For quantitative absorptions increasing numbers ofglioma cells were suspended in aliquots of a constant dilution of hybridoma supernatants and after incubation the remaining activity was measured by micro-ELISA. The absorption procedures have been described in detail elsewhere (Stavrou et al. 1983) .
RESULTS
Establishment and selection of antibody secreting hybridomas
From 2 fusion experiments between X63-Ag8.653 myeloma cells and immune spleen cells against glioma cells, hybrids appeared between 6 and 10 days following fusion and were seen in 151 wells of Linbro plates. Screening of the supernatants of these hybridoma cultures, composed of numerous single colonies, showed that in 24 wells hybrids were secreting antibodies reacting to giioma cells used for immunization as well as to different human target cells including embryonic cells.
Specificity analysis and isotyping of interesting monoclonal immunoglobulins
Selected hybridomas that secreted monoclonal antibodies binding to various target tumor cells were sequentially cloned 3 times by limiting dilution method. In each cloning step they were examined for specificity or cross-reactivity by testing culture supernatants for antibody binding to human tumor cells of different origin and human peripheral blood monocytes. The eleven murine clones (MUC) secreting antibodies which did not react with control cells were chosen for further specificity analysis. The selected clonal products described here were designated as MUC 1-3, MUC 2-3, MUC 3-3, MUC 4-3, MUC 5-3 and MUC 7-22, MUC 8-22, MUC 10-22, MUC 11-22, MUC 14-22, MUC 15-22 and MUC 2-63. During the specificity analysis of these 11 monoclonal anti-glioma antibodies it was observed that the hybridoma products MUC 1-3 to MUC 5-3 reacted not only with neuroectodermal tumors but also with normal brain tissue. Whereas the rest of the McAbs (MUC 7-22 to MUC 15-22 and MUC 2-63) reacted with neuroectodermal tumors but did not recognize normal brain except for a few cells in brain cortex particularly bordering on tumor tissue. In this regard it should be stressed that the antibodies MUC 7-22 to MUC 15-22 and MUC 2-63 also recognized human embryonic brain cells (Table 1) .
In order to ensure the specificity of the selected hybridoma products, a series of quantitative absorption experiments using glioma cells as well as normal brain tissue were performed. A representative sample of the obtained data showed that monoclonal antibodies secreted by the hybridoma clones MUC 7-22 and MUC 8-22 did not lose their binding capability to glioma cells, including the immunizing tumor cells, after absorption with normal human brain tissue. On the other hand, the quantitative absorption with giioma cells derived from the tumor used for immunization gradually reduced the binding activity of MUC 7-22 and MUC 8-22 to glioma cells.
By means of immunodiffusion and immunoelectrophoresis tests the McAbs MUC 7-22, MUC 8-22, MUC 10-22, MUC 11-22, MUC 14-22 and MUC 15-22 were 
Binding properties of McAbs to fixed and paraffin embedded tissue sections
The immunoreactions of the gliomas tested with the antibodies MUC 7-22 to MUC 15-22 are summarized in Table 2 (Table 3) . Tumor cells in areas with characteristic architectural and cytological features of well differentiated astrocytomas were usually stained and showed different staining intensities. In all positive cells the reaction product was localized in cytoplasm, whereas nuclei were ordinarily negative. No staining was obtained within the intercellular spaces, mononuclear infiltrates, necrosis, abnormal stromal reactions, vascular proliferations, and normal brain areas bordering on tumor tissue. 
Binding properties of McAbs to glioma cryosections
The characteristic binding design of McAbs MUC 7-22 to MUC 15-22 investigated on glioma frozen sections is shown in found with all gliomas, particularly with astrocytomas as listed in Table 2 .
Binding properties of McAbs to glioma cells and embryonic brain cells cultured in vitro
The series of ceil cultures tested include short-term cultures as well as permanent tumor cell lines. As shown in Table 4 , all McAbs bound with high capacity to cells derived from human gliomas, neuroblastomas, melanomas and from human embryonic brain anlage. No reaction was observed with non-neuroectodermal cell lines tested (Table 4 ) and with peripheral blood mononuclear cells. Concluding from the extinction data obtained by ELISA the antibodies MUC 8-22 and MUC 14-22 react strongly with the 2 glioblastoma cell lines (85HG-64, 85 HG-65) and in a lesser intensity with the rest of the tested glioma cultures. Strong binding was also observed with embryonic cells of different origin and especially with those from brain anlage.
The cellular distribution of glioma associated antigen(s) reacting with selected McAbs was studied by indirect immunofluorescence procedure on frozen sections of glioma tissue and also on cell cultures (Fig. 1) . In general, the labelling with MUC 2-63 antibody was very high and the fluorescent structures were localized predominantly on the cell surface and occasionally in the cytoplasm of native cells. On the other hand, the epitopes reacting with MUC 7-22 to MUC 15-22 were confined mainly to the cytoplasm near the cell membrane. Particularly in acetone-fixed cells labelling of cytoplasmic organelles with MUC7-22 to MUC 15-22 was remarkably strong, although unfixed cells were unlabelled or only marginally labelled.
Binding properties of McAb to glioma cells in flow cytometry analysis
Flow cytometry analysis gave an interesting staining pattern showing the heterogeneity of surface expression of the recognized antigen(s). As shown in Table 5 the percentage of stained cells differs from 16 to 65~o when our set of McAbs is tested on various glioma cell lines. Fig. 2 demonstrates the recognition pattern of MUC 7-22 to MUC 15-22 on the cell line 85HG-65.
DISCUSSION
The results presented here indicate that a series of hybridomas originated by fusing of X63-Ag8.653 murine myeloma cells with mouse splenocytes of mice sensitized against human astrocytomas. A number of the hybridomas obtained produced no detectable antibodies or they stopped producing them after a few in vitro passages. The majority of the immunoglobulin-producing hybridomas, however, secretes antibodies binding a large number of normal and transformed human cells.
Seven hybridoma clones (MUC 7-22 to MUC 15-22 and MUC 2-63) obtained using a novel immunization schedule were selected according to binding properties of their products with human neuroectodermal tissue under certain conditions. Namely, the binding capability of the McAbs was tested on sections of fresh and paraffinembedded (45 ° C) material as well as on short-time in vitro cultured brain and glioma cells. According to the results of different binding tests, the monoclonal products MUC 7-22 to MUC 15-22 recognized antigenic determinants which were commonly expressed on neoplastically transformed glia cells, normal cells of the embryonic brain anlage and a few cells in brain areas next to the tumor tissue. . Evaluated against the isotype control UPC 10 (dark field).
The binding results using paralTm and frozen sections as well as cell cultures indicated that an ideal screening method that allows the identification ofglioma antigens in native form, does not exist so far (Roholl et al. 1985; Taub et al. 1985) . As shown in Table 3 tissue sections from material fixed with various chemicals and embedded in paraffin have their limitations. Fixation with coagulative fixatives (Bouin's) or crosslinkers (e.g., formaldehyde) obviously alters tumor-associated membrane antigens so that they mostly cannot be recognized by monoclonal antibodies. From all fixatives used in this study methanol/acetone or the Karnovsky paraformaldehyde/glutaraldehyde mixture and paraffin embedding at 45 ° C have been shown to be acceptable procedures. It is also apparent that air-dried, frozen sections (Kemshead and Coakham 1983; Coakham et al. 1985) or cryosections mounted on slides, using a combination of drying at room temperature and fixation with cold acetone (5 min, 4 ° C), are to be preferred to paraffin sections. However, the cytological evaluation of immunostained frozen sections can certainly introduce considerable difficulties in the cell characterization and particularly in the distinction between normal, reactive and neoplastically transformed cells. Depending on the binding behaviour with human normal and malignant tissue of different organs, the generated antibodies could be divided into 2 groups; the first group comprising of 5 antibodies (MUC 1-3 to MUC 5-3) shows reactivity against a large series of normal and tumor tissues. The second group of antibodies (MUC 7-22 to MUC 15-22 and MUC 2-63) differed from the former one by showing restricted reactivity essentially with neuroectodermal tumor cells as well as with embryonic and fetal brain cells of human origin.
The results of investigations comparing immunostained tumor sections under varying conditions suggest that the variability concerning the number of antibody binding cells in frozen sections and paraffin preparations is relative. The fact that each fixation and paraffin embedding led to remarkable reduction of positive cells indicate that many of tumor associated target determinants are destroyed by the used procedures.
Based on the binding pattern of the antibodies MUC 7-22 to MUC 15-22 and MUC 2-63 to gliomas, the conclusion seems justified that these McAbs recognize different epitopes. This was confirmed by immunostaining of frozen and paraffin preparations of the same tumor, and cell cultures as well (Fig. 1, Table 3 ). Moreover, the binding behavior of preselected McAbs to human tumors of different origin (Tables 1 and 2) indicated that neuroectodermal tumors share similar antigens as described for spontaneous (Seeger et al. 1981; Carrel et al. 1982; de Muralt et al. 1985) and experimental neurogenic tumors (Stavrou et al. 1983) .
Particularly interesting is the observation that the McAbs obtained against astrocytomas (MUC 7-22 to MUC 15-22 and MUC 2-63) reacted not only with glioma cells but also with cells of the embryonic brain anlage, the fetal brain and other embryonic regions. Therefore, it is most likely that the antigens recognized by these antibodies represent oncoembryonal/oncofetal antigens expressed in cells during the prenatal period and also in brain tumor cells. These results correspond with observations reported by Wikstrand et al. (1982) and de Muralt et al. (1985) .
The fact that McAbs directed against gliomas recognize molecules expressed in glioma cells as well as in embryonic and fetal cells and even in reactive astrocytes (de Muralt et al. 1985) does not limit the application of such antibodies for immunodiagnostic purposes. Regarding the histological and cytological examination of brain malignancies and the analysis of tumor cells in the cerebrospinal fluid (Coakham et al. 1985) , well defined reagents, e.g. McAbs, provide valuable diagnostic tools. Although immunohistochemical studies are still in a preliminary stage, they are creating new perspectives for an objective intraoperative diagnostic service, especially in cases where only small fragments of biopsy material are available. Moreover, McAbs directed against molecules restricted to embryonal/fetal tissue and re-expressed in malignant transformed brain ceils may serve as carders for radionuclides and cytostatic or cytotoxic agents in evaluation of in vivo diagnostic and therapeutic approaches as recently demonstrated for spontaneous and experimental neurogenic tumors (Bourdon et al. 1984; Epenetos et al. 1985; Stavrou et al. 1985 Stavrou et al. , 1986a Bullard et al. 1986 ). According to the different staining pattern of our McAbs recognizing up to 65 ~o of the cells within a glioma line one has to consider the possibility to increase the amount of positive cells by using a combination of McAbs.
